From a patient advocacy organization perspective, was a very informative meeting. Learned a lot from presentations and networking that will inform how we can add value to the advocacy-patient-drug developer dialogue.
![aftd aftd](https://orphandrugsus22.orphandrugsus.com/wp-content/uploads/elementor/thumbs/aftd-o8tksh2s9hf6y2vis9incrkf4sicvileobt92o65q8.png)
Dr. Nadine Tutton
Scientific Director, Research, Association for Frontotemporal Degeneration
I was very impressed with the format, the content was interesting and well done. I felt I learned a lot and was glad to be able to attend.
![pharmolam pharmolam](https://orphandrugsus22.orphandrugsus.com/wp-content/uploads/elementor/thumbs/pharmolam-o8tks7oed52bpz96b5gdntxt6xsoqjk3b1ae9wk3gg.png)
Senior Director
Business Development at Pharm-Olam, LLC